Fgf8 is required for normal development of the nasal region. Here, we have used a candidate approach to identify genes that are induced in chick nasal mesenchyme in response to FGF signaling. Using an explant culture system, we show that expression of the transcription factors Tbx2, Erm, Pea3, and Pax3, but not Pax7, in nasal mesenchyme is regulated by ectodermal signals in a stage-dependent manner. Using beads soaked in recombinant FGF protein and an FGF receptor antagonist, we furthermore demonstrate that FGF signaling is necessary and sufficient for expression of Tbx2, Erm, Pea3, and Pax3, but has no effect on Pax7 expression. We also show that, within the nasal mesenchyme, competence to respond to FGF signaling is initially widespread and uniform but becomes restricted to regions normally exposed to FGF at later stages of development, coincident with changes in FGF receptor expression. Finally, we provide evidence that FGF8 also regulates Erm and Pea3 expression in the nasal placodes. Together, these results identify Tbx2, Erm, Pea3, and Pax3 as downstream targets of FGF signaling in the facial area and suggest that these genes may mediate some of the effects of FGF8 during development of the nasal region. © 2002 Elsevier Science (USA)
INTRODUCTION
The vertebrate face is a complex structure that consists of a large variety of diverse tissues in precisely defined spatial arrangements. During embryogenesis, the face develops from buds of tissue, the facial primordia, which surround the primitive mouth and the nasal placodes. The frontonasal mass, the lateral nasal process, and the maxillary processes grow out and partially fuse to form the upper jaw and nasal region in mammals and the upper beak in birds, while the mandibular primordia give rise to the lower jaw or beak. All facial primordia initially consist of a core of undifferentiated mesenchyme covered by ectoderm. The mesenchyme contains cells of neural crests and cranial mesodermal origin. Neural crest-derived cells give rise to the facial skeleton, whereas mesodermal cells mainly form facial muscles (Couly et al., 1992 (Couly et al., , 1993 Noden, 1978 Noden, , 1983 Noden, , 1988 .
Outgrowth of all facial primordia depends on epithelial mesenchymal interactions, and removal of the epithelium truncates facial development (Wedden, 1987) . In the first branchial arch (BA1), where these tissue interactions have been examined in more detail, numerous studies have now provided evidence that ectodermal signals regulate mesenchymal cell proliferation, survival, patterning, and differentiation. In turn, signals from the mesenchyme influence development of the ectoderm (for a review, see FrancisWest et al., 1998; Jernvall and Thesleff, 2000) . These studies also demonstrated that maxillary and mandibular mesenchyme can respond differently to the same signals. Therefore, the specificity of the response seems to be a property intrinsic to the mesenchymal cells and might be related to the origin of the neural crest cells along the anteriorposterior axis (Ferguson et al., 2000) .
Among the molecules implicated as epithelial signals regulating gene expression in BA1 mesenchyme are members of the FGF family, in particular FGF8 (reviewed by Jernvall and Thesleff, 2000) . Studies in which isolated mandibular mesenchyme was cultured in contact with beads soaked in FGF8 demonstrated that FGF8 can substitute for the ectoderm to promote cell survival, stimulate proliferation, and induce and maintain expression of a variety of genes. Several of these genes (e.g., Pax9, Dlx1, and Dlx2) are known to be required for normal mandibular and tooth development (Neubü ser et al., 1997; Peters et al., 1998 ; Thomas et al., 1997 Thomas et al., , 2000 . Tissue-specific gene-targeting experiments inactivating Fgf8 in BA1 ectoderm have recently demonstrated that FGF8 has a dual function during BA1 development. It promotes mesenchymal cell survival and induces a developmental program required for BA1 morphogenesis (Trumpp et al., 1999) .
Patterning and morphogenesis of the prospective midfacial and nasal region have so far received much less attention, even though this region is frequently affected in human craniofacial malformation syndromes, such as cleft lip/cleft palate, which occur with a frequency of 1 in 1000 newborns (Derijcke et al., 1996) . As in BA1, outgrowth of frontonasal mesenchyme requires ectodermal signals, and many of the same signaling molecules implicated in BA1 patterning are also expressed in midfacial ectoderm (Wedden, 1987) . In particular, Fgf8 and six other members of the FGF family are expressed in overlapping domains in the prospective nasal region, and Fgf8 expression correlates with areas of high cell proliferation and expansion in frontonasal mass mesenchyme (Bachler and Neubü ser, 2001; McGonnell et al., 1998) . In addition, FGF8 has recently been implicated as medial signal during olfactory pathway development (LaMantia et al., 2000) . Tissuespecific inactivation of Fgf8 in midfacial ectoderm and the underlying brain results in severe facial defects, including a midfacial cleft, indicating that Fgf8 is required for development of that region (A. Leibbrandt and M. Repitz, unpublished observations). However, in contrast to BA1, little is known about the genes induced in response to FGF signaling in the nasal region, and most of the genes known to be induced by FGF in BA1 are not expressed in that area.
In this study, we have used a candidate-gene approach and an in vitro explant culture system to identify a set of target genes of FGF signaling in chick nasal mesenchyme that may mediate some of the effects of FGF8 during development of the nasal region. In this, we have focused on the T-box, Pax, and Pea3 transcription factor families, which have been implicated with functions in patterning, the regulation of cell proliferation, cell survival, and cell differentiation during development (Smith, 1999; de Launoit et al., 1997) . All three gene families include members that have previously been shown to be regulated by FGF signaling in other contexts (Isaacs et al., 1994; Neubü ser et al., 1997; Peters et al., 1998; Trumpp et al., 1999; Munchberg and Steinbeisser, 1999) . Furthermore, the T-box gene Tbx2, the Pax genes Pax3 and Pax7, and the Ets genes Pea3 and Erm have been reported to be expressed during craniofacial development (Chapman et al., 1996; ChotteauLelievre et al., 1997; Gibson-Brown et al., 1998; Mansouri et al., 1996) . Here, we show that expression of Tbx2, Erm, Pea3, and Pax3 is regulated in response to FGF signaling.
MATERIALS AND METHODS

Embryos
Fertilized chicken eggs were obtained from a local farmer (Kern chicken farm, Alland, Austria). Eggs were incubated at 38 Ϯ 1°C, and embryos were staged according to Hamburger and Hamilton (1951) .
Explant Culture, Tissue Recombination, and Bead Implantation
All dissections were performed in cold L15 medium (Gibco BRL) by using electrolytically sharpened tungsten needles. To obtain tissue for explant culture, the prospective midfacial region consisting of forebrain, facial mesenchyme, and facial ectoderm including the nasal placodes, was isolated as schematically shown in Fig. 1 . For the separation of tissue layers, freshly explanted tissue was incubated on ice in 2.5% pancreatin (Gibco BRL) for 20 (stage 18 -22 embryos) to 25 (stage 23-24 embryos) minutes, washed three times with cold L15 medium supplemented with 10% horse serum, and then incubated on ice in serum-supplemented L15 medium for 10 min. Unless otherwise stated, the forebrain tissue was removed by using 27-gauge injection needles followed by further separation FIG. 1. Dissection of nasal explants. The encircled region (dashed line) was excised with sharpened tungsten needles, resulting in an explant initially consisting of ectoderm, mesenchyme, and brain tissue. After incubation in pancreatin, the brain, and as required also the ectoderm, was removed. Explants consisting of ectoderm and mesenchyme (A), mesenchyme (B), or mesenchyme on which a ball of ectoderm, or beads soaked in recombinant proteins or PBS had been placed (C) were then cultured on filters floating on culture medium.
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For focal application of recombinant proteins to facial explants, heparin acrylic beads (Sigma) were soaked in recombinant proteins and applied to facial explants as previously described (Neubü ser et al., 1997) . The following recombinant proteins were used: human FGF4 (50 g/ml to 1 mg/ml), human FGF5 (1 mg/ml), mouse FGF8b (1 mg/ml), human FGF9 (1 mg/ml), human FGF10 (1 mg/ml), human EGF (1 mg/ml), or human IGF1 (1 mg/ml) (all from R&D Systems, Minneapolis, MN). Su5402 (Calbiochem) was used at 25 M. At the end of the culture period (2-24 h), the explants were fixed in 4% paraformaldehyde and processed for whole-mount in situ hybridization.
For bead implantation into the facial area in ovo, a small cut was introduced into the ectoderm covering the lateral nasal region by using a tungsten needle. An FGF-soaked bead was then carefully placed between ectoderm and mesenchyme by using a glass capillary attached to a mouth-controlled pipette. After microsurgery, the eggs were closed with scotch tape and incubated until the desired stage.
Each experiment was performed at least twice, but more typically three to five times, and the total number of specimens examined for each experimental condition is indicated in Results.
RNA in Situ Hybridization
For whole-mount RNA in situ hybridization, embryos or explants were fixed, processed, and hybridized according to the protocol described by Henrique et al. (1995) . Digoxigenin-labeled anti-sense riboprobes were detected with alkaline phosphatasecoupled anti-digoxigenin antibodies by using BM purple (Boehringer Mannheim) as the color substrate. All specimens belonging to the same experiment were processed in parallel, and in each experiment, specimens hybridized with the same probe were stained for the same amount of time. Quantitative differences in expression levels under different experimental conditions were confirmed by processing the corresponding specimens in the same tube in at least one additional experiment. The plasmids used to prepare the antisense riboprobes employed in this study have previously been described: Fgf8 (Crossley et al., 1996) , Pax3, Pax7 (Goulding et al., 1993) , Tbx2 (Logan et al., 1998) , Pea3, Erm (Lin et al., 1998), Fgfr1, Fgfr2, and Fgfr3 (Patstone et al., 1993) . For expression analysis in embryos for each probe and stage described, a minimum of six embryos in at least three independent experiments were examined.
For RNA in situ hybridization on paraffin sections (6 m), embryos were processed, sectioned, and hybridized with digoxigenin-labeled riboprobes as described by Neubü ser et al. (1995) with some modifications. A detailed protocol is available upon request. For each gene and stage, serial sections of at least three embryos were analyzed.
RESULTS
Expression of Fgf8, Tbx2, Erm, Pea3, Pax3, and Pax7 during Midfacial Development As a first step to assess whether Tbx2, Erm, Pea3, Pax3, and Pax7 might be targets of FGF8 during midfacial development, we examined their expression patterns in the nasal area and compared them with the expression of Fgf8.
At stage 18, Fgf8 is widely expressed in midfacial ectoderm between the nasal placodes with slightly higher expression levels at the medial edge of the placodes (Figs. 2A and 2B) . Between stage 18 and stage 20, Fgf8 expression spreads along the edge of the nasal placodes into the lateral nasal process and is subsequently downregulated in midfacial ectoderm (data not shown). By stage 24, high levels of Fgf8 RNA are confined to a horseshoe-shaped domain surrounding the nasal pits and to a narrow line of ectoderm connecting the oral limits of both nasal pits (Fig. 2C,  arrowhead) .
At all stages analyzed, expression of Tbx2 in the facial region is restricted to the mesenchyme. At stage 18, Tbx2 is widely expressed in the midfacial region and becomes restricted to a horseshoe-shaped region of mesenchyme around the nasal pits at stage 24 with higher expression levels in the lateral nasal process (Figs. 2D-2F) .
Erm, Pea3, and Pax3 are also widely expressed in facial mesenchyme at stage 18. In addition, expression of all three genes is detected in the ectoderm surrounding the nasal pits. Erm and Pea3 are also expressed within the nasal placodes (Figs. 2G, 2H, 2J, 2K, 2M, and 2N) . At stage 24, expression of all three genes is upregulated in the mesenchyme surrounding the nasal pits with higher expression levels in the lateral nasal process, whereas expression in the facial midline has been downregulated. Ectodermal expression of all three genes at stage 24 is similar to the expression at stage 18 (Figs. 2I, 2L, and 2O; and data not shown).
Pax7 is expressed in the lateral nasal mesenchyme and in a stripe of mesenchymal cells extending from the dorsal midline into the lateral nasal region at stage 18 (Fig. 2P , arrow, and Fig. 2Q ). At stage 24, Pax7 expression is restricted to the lateral nasal process (Fig. 2R) .
In summary, this analysis shows that the expression domains of Tbx2, Erm, Pea3, and Pax3 in the nasal region at stage 18 considerably overlap with the expression domain of Fgf8, but extend further laterally. Such an overlap can also be detected at later stages, when expression of Tbx2, Erm, Pea3, and Pax3 becomes restricted to the mesenchyme around the nasal pits coincident with the restriction of Fgf8 expression to the ectoderm flanking the nasal pits.
Dependence of Mesenchymal Expression of Tbx2, Erm, Pea3, Pax3, and Pax7 on Ectodermal Signals
Expression of Tbx2, Erm, Pea3, Pax3, and Pax7 is detectable in mesenchyme directly underlying the facial ectoderm. In order to test whether this expression is regulated by signals from the ectoderm, the facial region from stage 18 embryos was dissected and cultured in vitro as schematically shown in Fig. 1 . In explants consisting of facial ectoderm and mesenchyme, expression of Tbx2 (n ϭ 29/29), Erm (n ϭ 16/16), Pea3 (n ϭ 21/21), Pax3 (n ϭ 17/17), and Pax7 (n ϭ 7/7) was readily detectable after 24 h in culture . If the mesenchyme was cultured without the ectoderm, expression of Tbx2 (n ϭ 17/17), Erm (n ϭ 12/12), Pea3 (n ϭ 17/17), and Pax3 (n ϭ 11/11) was lost (Figs. 3F-3I).
Pax7 expression, in contrast, was still detected in the areas corresponding to the lateral nasal process albeit at a reduced level ( Fig. 3J ; n ϭ 11/11). In explants from which the ectoderm was removed and then placed back in contact with the mesenchyme prior to culture, expression of Tbx2 (n ϭ 4/4), Erm (n ϭ 4/4), Pea3 (n ϭ 5/5), and Pax3 (n ϭ 4/4) was observed in mesenchyme adjacent to the replaced ectoderm ( Figs. 3K-3N ). Pax7 expression, however, was not induced in mesenchyme close to the ectoderm and was only observed in the lateral nasal region (Fig. 3O , n ϭ 9/9). These results indicate that maintenance of Tbx2, Erm, Pea3, and Pax3 expression in the nasal mesenchyme requires signals from the nasal ectoderm, whereas Pax7 expression in lateral nasal mesenchyme is independent of such signals. We next examined whether ectodermal signals are still required to maintain the expression of Tbx2, Erm, Pea3, Pax3, and Pax7 at later stages of development. For this purpose, we assayed for the expression of these genes in facial mesenchyme isolated from stage 24 embryos and cultured either in the presence or absence of the ectoderm. In the presence of the ectoderm, Tbx2 (n ϭ 14/14), Erm (n ϭ 13/13), Pea3 (n ϭ 9/9), and Pax3 (n ϭ 7/7) expression was strongly upregulated in the nasal pit area and Pax7 (n ϭ 10/10) expression in the lateral nasal processes (Figs. 3P-3T ). In stage 24 mesenchyme cultured without the ectoderm, Tbx2 expression was still detectable but upregulation of expression in the nasal pit area did not occur (Fig. 3U , n ϭ 7/7). Expression of Pea3 (n ϭ 6/6) and Pax3 (n ϭ 12/12) was also maintained, but expression of both genes in the region corresponding to the medial nasal process was reduced or absent (Figs. 3W and 3X) . Erm expression was severely downregulated and was only detected when explants were grossly overstained ( Fig. 3V ; and data not shown; n ϭ 10/10). Pax7 expression, in contrast, was indistinguishable from expression in explants consisting of ectoderm and mesenchyme (Fig. 3Y , n ϭ 7/7).
Together, these data indicate that the early expression of Tbx2, Erm, Pea3, and Pax3 in facial mesenchyme is maintained by signals from the overlying ectoderm. By stage 24, residual Tbx2, Pea3, and Pax3 but not Erm expression is maintained in the absence of such signals. Nevertheless, refinement of the expression patterns and local modulation of expression levels still require ectodermal signals, even at stage 24. The pattern of Pax7 expression is not influenced by ectodermal signals at any of the stages analyzed.
FGF8 Is Sufficient to Induce Expression of Tbx2, Erm, Pea3, and Pax3 in Facial Mesenchyme
Since Fgf8 is expressed in the facial ectoderm in a pattern that corresponds with the expression domains of Tbx2, Erm, Pea3, and Pax3 in the underlying mesenchyme, we investigated whether FGF protein is sufficient to substitute for the ectoderm to maintain expression of these genes. For this purpose, we isolated facial mesenchyme from stage 18 embryos and cultured it for 24 h in contact with heparin acrylic beads that had been soaked in FGF8 protein (1 g/l, FGF8 beads), PBS, or other growth factors. In explants cultured with FGF8 beads, Tbx2 (n ϭ 25/25), Erm (n ϭ 18/18), Pea3 (n ϭ 17/17), and Pax3 (n ϭ 20/20) RNA was readily detectable in a halo around the beads, regardless of where the beads had been placed on the explant (Figs. 4A-4D). For all four genes, similar results were obtained with beads soaked in FGF4 (20/20 for each gene) or FGF9 protein (7/7 for each gene) and with FGF concentrations between 50 ng/l and 1 g/l (data not shown). These results are consistent with previous studies showing that FGF4, -8, and -9 can substitute for each other in various assays (Cohn et al., 1995; Crossley et al., 1996; Kettunen et al., 1998; Neubü ser et al., 1997; Vogel et al., 1996) . In contrast, beads soaked in PBS (n Ն 9 for each gene), FGF5, FGF10, EGF, and IGF1 (n Ն 3 for each gene) never did induce expression of any of the genes studied (Figs. 4F-4J; and data not shown). No Pax7 expression was ever observed around FGF8 beads placed medially into the region normally devoid of Pax7 expression. Beads placed into the lateral nasal region, where Pax7 is expressed independent of ectodermal signals, occasionally resulted in a slight upregulation of Pax7 expression but generally had no significant effect on the level of Pax7 expression in mesenchyme close to the bead (Fig. 4E , n ϭ 9/9). Together, these data show that, at stage 18, FGF8 protein, as well as FGF4 and FGF9 proteins, are sufficient to maintain expression of Tbx2, Erm, Pea3, and Pax3 in nasal mesenchyme. At that stage, the mesenchyme in the midfacial region is uniformly competent to respond to FGF signals by expressing these genes.
We next examined whether FGF would still have an effect on the expression of Tbx2, Erm, Pea3, and Pax3 at stage 24 when Tbx2, Pea3, and Pax3 expression is no longer completely dependent on ectodermal signals. In stage 24 mesenchyme cultured in contact with FGF8 beads for 24 h, Tbx2 (n ϭ 10/10), Erm (n ϭ 9/9), Pea3 (n ϭ 8/8), and Pax3 (n ϭ 9/9) RNA was detected around the beads. However, the level of induction was dependent on the position of the bead. Beads placed into the lateral region, where Tbx2, Erm, Pea3, and Pax3 are coexpressed with Fgf8 at high levels at the time of explantation, resulted in a strong upregulation of expression in the surrounding mesenchyme. In contrast, only low levels of expression were detected around beads placed into the medial region (Figs. 4K-4O) . Expression of Pax3 in particular was hardly detectable at all (Fig. 4N) . These data indicate that, at stage 24, competence of the nasal mesenchyme to respond to FGF signaling is no longer uniform. At that stage, FGF8 can still upregulate expression of Tbx2, Erm, Pea3, and Pax3 laterally in the region normally exposed to FGF8, but can only weakly induce expression in medial mesenchyme, where Fgf8 is no longer expressed in the overlying ectoderm.
Finally, in order to confirm the effect of FGF on the expression of Tbx2, Erm, Pea3, and Pax3 in the context of the living embryo, FGF4 or FGF8 beads were implanted dorsolaterally or medially of the right nasal placode of stage 18 -20 embryos in ovo. Embryos were then assayed for an upregulation or ectopic expression in the vicinity of the beads. In embryos dissected 8 or 24 h after FGF bead implantation at stage 18 -19, expression of Tbx2 (n ϭ 20), Erm (n ϭ 7), and Pea3 (n ϭ 8) was upregulated around the implanted beads and was also induced in areas that showed no expression on the unmanipulated side (Figs. 4P-4R, arrows; and data not shown). Implantation of FGF beads also resulted in an extension of the Pax3 expression domain (n ϭ 12). The effect, however, was much less pronounced than for the other three genes and was restricted to beads placed relatively close to the nasal placodes (Fig. 4S) . Implantation of PBS beads had no effect on the expression of any of the four genes ( Fig. 4T ; and data not shown, n ϭ 5 per gene). These results show that FGF beads can not only substitute for facial ectoderm to maintain Tbx2, Erm, Pea3, and Pax3 expression in facial mesenchyme in vitro, but can induce ectopic expression of these genes in the facial area in ovo.
FGF-Receptor Expression in the Nasal Region between Stages 18 and 24
It has previously been reported that FGF receptors Fgfr1-Fgfr3 are expressed during facial development (Wilke et al., 1997) . In order to assess whether changes in FGF receptor expression might be responsible for the observed stagedependent change in competence of the nasal mesenchyme to respond to FGF, we compared the expression of Fgfr1-Fgfr3 at stages 18 and 24 by in situ hybridization. At stage 18, Fgfr1 was widely expressed in the nasal mesenchyme and ectoderm, at uniform levels in the lateral and medial nasal region (Fig. 5A) . At that stage, expression of Fgfr2 was below the level of detection (Fig. 5C ). In contrast, at stage 24, expression of Fgfr1 in the lateral nasal process and at the lateral edge of the medial nasal process was much higher than expression close to the facial midline (Fig. 5B) . Widespread expression of Fgfr2 in the facial mesenchyme and ectoderm with slightly stronger expression in the center of the frontonasal mass was also detectable at that stage (Fig.  5D ). Fgfr3 expression was undetectable in the nasal area at both stages examined, but was detected in the developing forebrain (data not shown). These results identify changes in the expression of Fgfr1 as one possible cause for the observed changes in competence of the mesenchyme to respond to FGF8.
FGF Can Upregulate Expression of Erm and Pea3 in the Nasal Placode
Erm, Pea3, and Pax3 are not only expressed in facial mesenchyme but also in the facial ectoderm overlapping with Fgf8 expression. In addition, Erm and Pea3 are also expressed throughout the nasal placode, which is surrounded by Fgf8-expressing ectoderm but does not express Fgf8 itself (Figs. 2B, 2H, and 2K) . Pax3, in contrast, is only expressed at the edge of the placode (Fig. 2N) . In order to explore whether Erm and Pea3 expression within the nasal placode is regulated by FGF signaling, the central part of stage 19 nasal placodes (using the developing olfactory nerve as a landmark and aiming at excluding the Fgf8-and Pax3-positive ectoderm surrounding the placode) was dissected and cultured on top of stage 19 facial mesenchyme for 24 h. In such explants, expression of Erm, Pea3, and Pax3 in the nasal placode was undetectable after culture (Figs. 6A-6C; n ϭ 8/8 for each gene). If, however, an FGF4 or FGF8 bead was placed next to the placode, expression of Erm and Pea3 was readily detectable in the placode and the mesenchyme surrounding the FGF bead (Figs. 6D, 6E , 6G, and 6H, n ϭ 12/12 each). Pax3 expression, in contrast, was only detectable in the mesenchyme but not in the nasal placode (Figs. 6F and 6I, n ϭ 8/8 each). These results suggest that expression of Pea3 and Erm in the nasal placode requires the presence of the surrounding ectoderm and that proximity to a source of FGF8, is sufficient for maintaining and upregulating placodal Pea3 and Erm expression.
FGF Signaling Is Required for the Expression of Tbx2, Erm, Pea3, and Pax3 in the Nasal Region
In order to examine whether FGF signaling is not only sufficient but is also required for the maintenance of Tbx2, Erm, Pea3, and Pax3 expression in the nasal region, we used Su5402, a specific inhibitor of FGF signaling, to block FGF signaling in explants cultured in vitro. Su5402 has previously been used to study the function of FGF signaling in vitro and in ovo (Mohammadi et al., 1997; Muhr et al., 1999; Norlin et al., 2000; Rodriguez Esteban et al., 1999; Schneider et al., 1999; Wilson et al., 2000) . Su5402 binds to the ATP binding pocket of the FGF receptor kinase domain and prevents receptor tyrosine phosphorylation by functioning as a competitor to ATP. In the range of 10 -200 M, it did not inhibit tyrosine phosphorylation of the insulin receptor or the EGF receptor, and only weakly inhibited the PDGF receptor at high concentrations (Mohammadi et al., 1997) .
Facial explants consisting of ectoderm and mesenchyme were isolated from embryos at stage 18 or stage 24 and cultured for 8 h in the presence or absence of 25 M Su5402 in the culture medium. In stage 18 explants cultured in the presence of Su5402, little or no expression of Tbx2 (n ϭ 10/10), Erm (n ϭ 9/10), Pea3 (n ϭ 7/7), and Pax3 (n ϭ 12/12) was detectable at the end of the culture period (Figs. 7A-7D and 7F-7I). In contrast, expression of Pax7 was still readily detectable in the lateral region of explants cultured in the presence of Su5402, albeit at slightly lower levels than in controls (Figs. 7E and 7J, n ϭ 6/7). In order to exclude that the failure to detect Tbx2, Erm, Pea3, and Pax3 RNA in Su5402-treated explants is the consequence of a toxic effect of Su5402 on the facial tissue (e.g., the induction of massive cell death), we examined whether this loss of expression is reversible. For this purpose, stage 18 explants were first cultured for 8 h in the presence of Su5402 and then allowed to recover for an additional 16 h in the absence of the inhibitor. In such explants, expression of Tbx2 (n ϭ 11/11), Erm (n ϭ 6/6), Pea3 (n ϭ 8/8), and Pax3 (n ϭ 6/6) was readily detectable in similar patterns as in explants cultured in the absence of the inhibitor throughout the 24-h culture period (Figs. 7K-7N ). These data therefore indicate that FGF signaling is required for the maintenance of Tbx2, Erm, Pea3, and Pax3 expression at stage 18.
In stage 24 explants cultured in the presence of Su5402, expression of Tbx2 was still readily detectable. However, as in stage 24 mesenchyme cultured in the absence of the ectoderm, no upregulation of Tbx2 expression in the mesenchyme flanking the nasal placodes was observed (Figs. 7O and 7T, n ϭ 4/4). Expression of Erm was barely detectable in the mesenchyme of Su5402-treated explants, but expression in the nasal placodes was maintained (Figs. 7P and 7U, n ϭ 6/7). Pea3 expression was undetectable in Su5402-treated explants (Figs. 7Q and 7V, n ϭ 8/8). In contrast, Pax3 (n ϭ 6/6) and Pax7 (n ϭ 4/4) expression in Su5402-treated explants was indistinguishable from the expression in control explants (Figs. 7R, 7S , 7W, and 7X). These results show that, at stage 24, FGF signaling is not required for the expression of Pax3 and Pax7 in facial mesenchyme. Upregulation of Tbx2 in the nasal pit area and mesenchymal expression of Erm and Pea3 still require FGF signaling at this stage.
DISCUSSION
Ectodermal Signals Establish and Maintain Spatially Restricted Gene Expression Patterns in the Nasal Area
Studies on the function of signals and tissue interactions in cultured tissue explants and mutant mice have recently significantly increased our understanding of the mechanisms involved in patterning the first branchial arch (BA1). It is now a well-accepted idea that signals from the epithe- 
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As in BA1, the mesenchyme in the nasal/midfacial region is also derived from the neural crests but patterning of that region is less well understood (Le Douarin, 1982; Noden, 1983; Osumi-Yamashita et al., 1994) . Tissue recombination and transplantation experiments in ovo had suggested that outgrowth of the nasal mesenchyme depends on signals from the overlying ectoderm (Wedden, 1987) . Recently, a study using mouse nasal explants has implicated FGF8, SHH, and BMP4 as three ectodermal signals that act together to control patterning and cell differentiation in the olfactory pathway (LaMantia et al., 2000) . Here, we show that expression of the transcription factors Tbx2, Erm, Pea3, and Pax3 in nasal mesenchyme at stage 18 depends on signals from the nasal ectoderm since expression of these genes was lost in mesenchyme cultured in isolation. In contrast, expression of Pax7 was maintained in nasal mesenchyme cultured for 24 h in the absence of the ectoderm. These results show that, at stage 18, many aspects of patterning of the nasal mesenchyme are still plastic and require inductive signals from the ectoderm for maintenance. This seems still to be true, although to a lesser extent, even at stage 24. At that stage, ectodermal signals are still required for the upregulation of expression of Tbx2, Erm, and Pea3 in a horseshoe-shaped domain of mesenchyme surrounding the nasal pits.
On the other hand, an initial differential specification of medial and lateral nasal mesenchyme seems already to have occurred at stage 18, as indicated by the maintenance of Pax7 expression in lateral nasal mesenchyme in the absence of the ectoderm. Whether this pattern of Pax7 expression is initially set up in response to inductive signals from the ectoderm or whether it is the result of different origins along the anterior-posterior axis of the neural crest cells populating the lateral and the medial nasal region remains to be examined. We detected Pax7 expression already in streams of neural crest cells emigrating from the fore-and midbrain into the lateral nasal region, and a similar pattern of expression has also been described for a knock-in of LacZ into the Pax7 locus in the mouse (Mansouri et al., 1996) . Pax7 may therefore already be expressed in prospective lateral nasal cells before they reach the lateral nasal region.
Interestingly, our findings regarding the regulation of Pax7 expression differ from the results described by LaMan- et al. (2000) , who were unable to detect Pax7 expression in E9.0 mouse nasal mesenchyme cultured for 48 h in the absence of the nasal ectoderm. One possible explanation for these apparently conflicting findings is the difference in the length of culture, since the loss of Pax7 might be a late consequence of the loss of inductive signals required, e.g., for the maintenance of lateral nasal fates. Alternatively, differences in the developmental timing when the nasal mesenchyme was isolated may also be responsible for the differing results. In fact, E9.0 in the mouse may correspond to a slightly younger stage in the chick than stage 18 used in this study. Finally, species-specific difference in the regulation of Pax7 expression can also not be ruled out.
FGF-Signaling Regulates Expression of Tbx2, Erm, Pea3, and Pax3 in Nasal Mesenchyme
Using an FGF receptor antagonist, we have shown that, at stage 18, FGF signaling is required to maintain expression of these genes in nasal mesenchyme in the presence of the ectoderm. Furthermore, beads soaked in recombinant FGF4, -8, or -9 protein were sufficient to substitute for the ectoderm to maintain expression of these genes in stage 18 nasal mesenchyme explanted in vitro, to upregulate expression of these genes in the nasal pit area of stage 24 mesenchyme explants, and to induce ectopic expression when transplanted into the facial area of stage 18 embryos in ovo. These results together strongly suggest that FGFs produced in the nasal ectoderm regulate expression of Tbx2, Erm, Pea3, and Pax3 in the underlying mesenchyme.
We have also shown that Fgf8 is expressed in a pattern generally consistent with functioning as an epithelial signal that regulates Tbx2, Erm, Pea3, and Pax3 expression in vivo. However, the fibroblast growth factor family now consists of 22 members (reviewed by Ornitz and Itoh, 2001; Powers et al., 2000) and we have recently shown that 7 (Fgf3, Fgf8, Fgf9, Fgf10, Fgf15, Fgf17, and Fgf18) are expressed in partially overlapping domains during mouse midfacial development (Bachler and Neubü ser, 2001 ). In particular, Fgf9 and Fgf10 showed patterns that closely resembled the Fgf8 expression pattern around the nasal placodes. Both genes were, however, already expressed lateral of the nasal placodes slightly earlier than Fgf8. In our in vitro assay, FGF4, -8, and -9, but not FGF10, were all equally sufficient to maintain expression of Tbx2, Erm, Pea3, and Pax3, in line with previous studies showing that FGF4, -8, and -9, but not FGF10, can perform the same biological functions in a variety of developmental contexts (Cohn et al., 1995; Crossley et al., 1996; Kettunen et al., 1998; Neubü ser et al., 1997; Vogel et al., 1996) . It is therefore very likely that the expression of mesenchymal targets of FGF signaling in the developing face is regulated by the combined action of several members of the FGF family, including both FGF8 and FGF9. Fgf9 has so far not been cloned from the chick. Assuming that its expression pattern in the chick resembles that in the mouse, FGF9 might be responsible for the early expression of Tbx2, Erm, Pea3, and Pax3 in the lateral nasal region, when Fgf8 expression is still restricted to the medial nasal area. At later stages, expression would then be maintained by both FGF8 and FGF9 together. In other regions with coexpression of several FGFs, such as the midhindbrain boundary or the apical ectodermal ridge of the limb bud, gene targeting experiments have recently provided evidence for partially redundant functions of different FGFs (Moon et al., 2000; Sun et al., 2000; Xu et al., 2000) . Knockouts of individual members of the FGF family in the facial ectoderm may therefore not result in a complete loss of expression of genes that nevertheless require FGF signaling.
We found that expression of Tbx2, Erm, Pea3, and Pax3 is induced around FGF beads within 4 h of bead application (data not shown). This kinetic of induction is significantly slower than the induction of Sprouty-2 by FGF, which has been suggested to be a primary response target of FGF signaling and is induced within 1 h after bead application (Minowada et al., 1999) . It is therefore currently unclear whether any of the four genes analyzed is a direct target of FGF signaling. Unfortunately, experiments aimed at addressing this possibility were unsuccessful due to poor survival of early facial tissue in the presence of cycloheximide. Tbx2, Erm, Pea3, and Pax3 induction does, however, occur quickly enough to act upstream of morphological changes rather than being the consequence of pushing cell differentiation into a particular direction.
Even though our results strongly point toward an essential function of FGF signaling in the regulation of Tbx2, Erm, Pea3, and Pax3 expression during nasal development, we cannot exclude that additional epithelial signals are involved in the regulation of these genes. Such signals could, e.g., modify the mesenchymal response to FGF by synergizing with or antagonizing FGF signaling, as it has been described for the antagonistic regulation of Pax9 expression by FGF and BMP signaling during tooth development (Neubü ser et al., 1997) . Our finding that Pax3 expression dorsomedial of the nasal pit was downregulated in mesenchyme cultured in the absence of the ectoderm, but maintained in explants consisting of ectoderm and mesenchyme cultured in the presence of an FGF signaling inhibitor in fact suggests that epithelial signals other than FGF contribute to the regulation of Pax3 expression at that stage. Likewise, we also found that some Pea3 expression was maintained in stage 24 mesenchyme in the absence of the ectoderm, whereas expression was completely lost in explants consisting of mesenchyme and ectoderm in the absence of FGF signaling. The regulation of Pea3 expression therefore also seems to be more complex and may, for example, involve inhibitory signals from the ectoderm that downregulate Pea3 expression in the absence of FGF signaling.
In all our experiments, FGF-soaked beads had no significant effect on the expression of Pax7 in the nasal area, going in line with our finding that the expression domain of Pax7 in the lateral nasal mesenchyme is maintained in the absence of ectodermal signals. LaMantia et al. (2000) also studied the effect of FGF8 on Pax7 expression using a somewhat different experimental set up. They describe that the size of the Pax7 expression domain was expanded by 40% in E9.0 mouse nasal explants consisting of ectoderm and mesenchyme cultured for 48 h in the presence of an FGF8b function-blocking antibody. Conversely, in explants that were cultured in the presence of 100 ng/ml FGF8b in the medium, they found a 45% decrease in the Pax7 domain. A difference in the developmental timing when the explants were isolated and the much longer culture time of LaMania et al. (2000) are the most likely reasons why they observe effects of FGF signaling on the Pax7 expression domain, whereas we did not.
Stage Dependence of the Mesenchymal Competence to Respond to FGF Signaling
We have found that the competence of the nasal mesenchyme to respond to FGF signaling by expression of Tbx2, Erm, Pea3, and Pax3 is initially uniform. It therefore appears that, at stage 18, the expression patterns of ectodermal signals determine where these genes are expressed in the mesenchyme. At later stages, however, mesenchyme in the nasal pit region and the facial midline shows differential responses. Whereas exposure of nasal pit mesenchyme to FGF still results in a strong upregulation of expression, no or only a weak induction is observed after exposure of mesenchyme in the facial midline to FGF. Since Fgf8 expression disappears from midfacial ectoderm and becomes restricted to a horseshoe-shaped domain surrounding the nasal pits by stage 24, only the mesenchyme that is still exposed to FGF at that stage seems to maintain the competence to respond to FGF signaling. Similar findings have been described by Ferguson et al. (2000) for the mouse mandibular arch. There, prior to E10.5, the mesenchyme also proved to be equally competent to respond to FGF8 by activating transcription of genes such as Dlx2, Dlx5, Msx1, or Barx1. At a later stage, however, expression of these genes could only be maintained within the endogenous expression domains and ectopic expression could no longer be induced. Therefore, the induction of regional gene expression in an initially equicompetent mesenchyme in response to regional ectodermal signals seems to be a common feature in patterning of the neural crest-derived facial mesenchyme. We have found that expression of Fgfr1 is initially ubiquitous and uniform within the nasal mesenchyme but then becomes strikingly downregulated in regions that lose competence. Therefore, changes in Fgfr expression patterns may be one of the molecular alterations that underlie the stage-dependent change in competence. Further studies will be required to determine whether this downregulation of Fgfr1 in the facial midline is necessary and sufficient for the observed competence change or whether additional alterations are also involved.
FGF Signaling Influences Gene Expression in the Nasal Placodes
Between stages 18 and 24, Fgf8 is expressed at high levels in the ectoderm adjacent to the nasal placodes, but not in the placodes themselves. At the same time, Erm and Pea3 are expressed in the nasal placodes, the ectoderm surrounding them, and the nasal mesenchyme. Erm and Pea3 expression is downregulated in stage 18 nasal placodes cultured separately from the Fgf8-positive ectoderm surrounding them, but both genes are expressed at high levels in placodes cultured adjacent to an FGF bead. In addition, Pea3 and Erm expression is also lost from the nasal placodes of stage 18 explants cultured in the presence of Su5402. Together, these observations strongly suggest that FGF signaling regulates the expression of Pea3 and Erm in the nasal placodes at stage 18. Whether FGF8 functions as a planar signal that directly acts on the nasal placode ectoderm to control expression of Erm and Pea3 or whether it exerts its effect indirectly via the induction of secondary signals in the nasal mesenchyme remains to be investigated.
The Role of Tbx2, Erm, Pea3, and Pax3 in Midfacial Development FGF signaling is essential for normal development of the midfacial region. Embryos compound heterozygous for a hypomorphic and a null allele of Fgf8 and embryos with a tissue-specific knockout of Fgf8 in the facial area develop severe midfacial malformations (Meyers et al., 1998; A. Leibbrandt and M. Repitz, unpublished observations) . Our results clearly identify Tbx2, Erm, Pea3, and Pax3 as target genes of FGF signaling in the nasal mesenchyme and therefore suggest that these genes may function as direct or indirect downstream mediators of FGF signaling in the face. Mutations in PAX3 are responsible for the severe malformations in human patients with Waardenburg's syndrome (reviewed by Dahl et al., 1997) . These patients typically present craniofacial abnormalities, including dystopia canthorum, prominent nasal root, cleft lip and highly arched palate, pigmentation deficiencies, and sensorineural deafness (McKusick, 1992) . PAX3 is therefore essential for normal development of cranial neural crest-derived structures. In the mouse, heterozygous Pax3 mutants (Splotch mutants) show only in minor facial phenotypes (Asher et al., 1996) . Homozygous mutants, however, show gross alterations of facial structures derived from the neural crest but die at midgestation precluding analysis of the facial skeleton (Auerbach, 1954) . Since several examples of redundancy among Pax genes belonging to the same subfamily have been described, it cannot currently be ruled out that Pax3 and Pax7 may serve partially redundant functions in the lateral nasal region where they are coexpressed (Bouchard et al., 2000; Peters et al., 1999) .
Mice in which the Tbx2 or Erm genes have been inactivated are not yet available. Pea3-deficient mice are viable and phenotypically normal, but males are infertile (Laing et al., 2000) . Since Pea3, Erm, and Er81, the third member of the Pea3 subfamily of Ets transcription factors, are structurally closely related and expressed in very similar patterns, partial redundancy between these genes can be expected (Chotteau-Lelievre et al., 1997; de Launoit et al., 1997) . The generation of double and triple mutants may therefore be required to study their function in facial development. A detailed analysis of the mutant phenotypes of the targets of FGF signaling identified in this study, and of their closely related genes, will ultimately contribute to a better understanding of the role of FGF signaling during midfacial development.
